One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.
Joensuu H, et al. Among authors: vehtari a.
JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347.
JAMA. 2012.
PMID: 22453568
Clinical Trial.